Citations

Clear

1526 citation(s) found for "Sun, Bo".

Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy
Chen, Kexin , Yang, Da , Li, Xiangchun , Sun, Baocun , Song, Fengju , Cao, Wenfeng , Gao, Zhibo, Li, Haixin , Liang, Han , Zhao, Yanrui, Li, Miao , Buckner, Jan C. , Patterson, Scott D. , Reinhard, Christoph , Bhathena, Anahita, Joshi, Deepa, Wang, Yi Michael, Raghavakaimal, Sreekumar, Lü, Xin , Chang, Han , Ba, Sujuan, Luo, Longhai, Cavenee, Webster K. , Zhang, Wei , Hao, Xishan , Chen, Kexin , Buckner, Jan, Sun, Baocun , Brat, Daniel J. , Zheng, Hong , Ye, Xiang , Mischel, Paul S. , Croce, Carlo Maria , Li, Hui , Pan, Yang , Chen, Kexin

Mayo Clinic

Proceedings of the National Academy of Sciences | January 13, 2015 | Volume: 112 | Issue: 4 | Pages: 1107-1112

10.1073/pnas.1422640112 | PMID 25583476 Get It

Significance We have identified a lethal subtype of gastric cancer (GC) that is characterized by high levels of clonal heterogeneity and TP53 (tumor protein P53) mutation. We have also uncovered key novel mutations in the targetable NRG1 (neuregulin-1) and ERBB4 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 4) ligand-receptor pair and identified BRCA2 (breast cancer 2, early onset) mutations as new genetic markers to predict better survival for GC. Our study represents a novel approach for GC personalized medicine and identified novel clinical actionable therapies for GC therapy.
Management of chronic neuropathic pain: a protocol for a multiple treatment comparison meta-analysis of randomised controlled trials
Mulla, Sohail, Buckley, D. Norman , Moulin, Dwight E. , Couban, Rachel , Izhar, Zain, Agarwal, Arnav , Panju, Akbar, Wang, Li , Kallyth, Sun Makosso, Turan, Alparslan , Montori, Víctor M. , Thabane, Lehana , Busse, Jason W. , Agarwal, Arnav , Sessler, Daniel I. , Guyatt, Gordon , Montori, Victor M , Thabane, Lehana

Mayo Clinic

BMJ Open | November 21, 2014 | Volume: 4 | Issue: 11 | Pages: e006112

10.1136/bmjopen-2014-006112 | PMID 25412864 Get It

Introduction Chronic neuropathic pain is associated with reduced health-related quality of life and substantial socioeconomic costs. Current research addressing management of chronic neuropathic pain is limited. No review has evaluated all interventional studies for chronic neuropathic pain, which limits attempts to make inferences regarding the relative effectiveness of treatments. Methods and analysis We will conduct a systematic review of all randomised controlled trials evaluating therapies for chronic neuropathic pain. We will identify eligible trials, in any language, by a systematic search of CINAHL, EMBASE, MEDLINE, AMED, HealthSTAR, DARE, PsychINFO and the Cochrane Central Registry of Controlled Trials. Eligible trials will be: (1) enrol patients presenting with chronic neuropathic pain, and (2) randomise patients to alternative interventions (pharmacological or non-pharmacological) or an intervention and a control arm. Pairs of reviewers will, independently and in duplicate, screen titles and abstracts of identified citations, review the full texts of potentially eligible trials and extract information from eligible trials. We will use a modified Cochrane instrument to evaluate risk of bias of eligible studies, recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) to inform the outcomes we will collect, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to evaluate our confidence in treatment effects. When possible, we will conduct: (1) in direct comparisons, a random-effects meta-analysis to establish the effect of reported therapies on patient-important outcomes; and (2) a multiple treatment comparison meta-analysis within a Bayesian framework to assess the relative effects of treatments. We will define a priori hypotheses to explain heterogeneity between studies, and conduct meta-regression and subgroup analyses consistent with the current best practices. Ethics and Dissemination We do not require ethics approval for our proposed review. We will disseminate our findings through peer-reviewed publications and conference presentations. Trial registration number PROSPERO (CRD42014009212).
The Rare Cancer Network: Ongoing Studies and Future Strategy
Özşahin, Mahmut , Mirimanoff, René-Olivier, Thariat, Juliette , Sun, Xu , Atalar, Banu , Lassen–Ramshad, Yasmin , Uğurluer, Gamze , Hallemeier, Christopher L. , Houtte, Paul Van , Krengli, Marco , Zhang, Lan Jun, Funk, Ryan K., Rooney, Jessica, Miller, Robert C. , Hallemeier, Christopher, Chang, Kenneth , Funk, Ryan, Mirimanoff, R.O., Krishnan, Sunil , Hallemeier, Christopher Leigh , Chang, Kenneth Tou En , Thariat, Juliette

Mayo Clinic

Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 91-94

10.4081/rt.2014.5465 | PMID 25276326 Get It

The Rare Cancer Network (RCN) was formed in the early 1990's to create a global network that could pool knowledge and resources in the studies of rare malignancies whose infrequency prevented both their study with prospective clinical trials. To date, the RCN has initiated 74 studies resulting in 46 peer reviewed publications. The First International Symposium of the Rare Cancer Network took place in Nice in March of 2014. Status updates and proposals for new studies were heard for fifteen topics. Ongoing studies continue for cardiac sarcomas, thyroid cancers, glomus tumors, and adult medulloblastomas. New proposals were presented at the symposium for primary hepatic lymphoma, solitary fibrous tumors, Rosai-Dorfman disease, tumors of the ampulla of Vater, salivary gland tumors, anorectal melanoma, midline nuclear protein in testes carcinoma, pulmonary lymphoepithelioma-like carcinoma, adenoid cystic carcinoma of the trachea, osteosarcomas of the mandible, and extra-cranial hemangiopericytoma. This manuscript presents the abstracts of those proposals and updates on ongoing studies, as well a brief summary of the vision and future of the RCN.
History of the Rare Cancer Network and past Research
Mirimanoff, René-Olivier, Özşahin, Mahmut , Thariat, Juliette , Özyar, Enis , Schick, Ulrike , Pehlivan, Berrin , Krengli, Marco , Franzetti-Pellanda, Alessandra , Vees, Hansjörg, Scandolaro, Luciano , Belkacémi, Yazid , Villà, S. , İğdem, Şefik , Lutsyk, Myroslav, Miller, Robert C. , Mirimanoff, R.O., Cai, Ling , Thariat, Juliette

Mayo Clinic

Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 86-90

10.4081/rt.2014.5462 | PMID 25276325 Get It

Approximately, twenty years ago, the Rare Cancer Network (RCN) was formed in Lausanne, Switzerland, to support the study of rare malignancies. The RCN has grown over the years and now includes 130 investigators from twenty-four nations on six continents. The network held its first international symposium in Nice, France, on March 21-22, 2014. The proceedings of that meeting are presented in two companion papers. This manuscript reviews the history of the growth of the RCN and contains the abstracts of fourteen oral presentations made at the meeting of prior RCN studies. From 1993 to 2014, 74 RCN studies have been initiated, of which 54 were completed, 10 are in progress or under analysis, and 9 were stopped due to poor accrual. Forty-four peer reviewed publications have been written on behalf of the RCN.
Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology
Rigby, Heather, Dugger, Brittany N. , Hentz, Joseph G. , Beach, Thomas G. , Shill, Holly A. , Driver‐Dunckley, Erika , Sue, Lucia I., Caviness, John N., Rigby, Heather B, Driver-Dunckley, Erika, Adler, Charles H. , Sabbagh, Marwan Noel , Dugger, Brittany N

Mayo Clinic

Movement Disorders Clinical Practice | October 29, 2014 | Volume: 2 | Issue: 1 | Pages: 33-38

10.1002/mdc3.12104 | PMID 30363831 Get It

Abstract The pathologic changes of Parkinson's disease ( PD ) and Progressive Supranuclear Palsy (PSP) have been reported to coexist, but whether PSP pathology modifies the clinical course of those individuals is unknown. The aim of this study was to determine whether clinical features of pathologically confirmed PD subjects with concomitant PSP pathology differ from those with PD alone. Subjects enrolled in the Arizona Study of Aging and Neurodegenerative Disorders had annual movement and cognitive evaluations from enrollment until death/autopsy. All cases between 1997 and 2014 with a final clinicopathological diagnosis of PD with or without PSP at autopsy were analyzed. Overall, 12 of the 125 cases with pathologically confirmed PD had coexisting PSP pathology (9.6%). Those with PD ‐ PSP had more‐prominent postural instability, body bradykinesia, difficulty arising from a chair, and falls; asymmetric onset was less common in this group. Downgaze palsy and square wave jerks were infrequent in both groups. Gender, age at death, disease duration, rate of dementia, and presence of rest tremor did not differ between groups. Only 58% of subjects in the PD ‐ PSP group were correctly given a final diagnosis in life of PD, compared to 91% of those with PD alone. The combination of PD and PSP pathology yields a heterogeneous clinical syndrome that often resembles PD, but may be more symmetric at onset and have more‐prominent postural instability and falls. Our observations suggest that coexisting PSP pathology may be an important factor contributing to the clinical heterogeneity in PD and a potential confounder in diagnosis.
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials
Moghadam, Setareh H., Roe, Allyson D., Sun, Chung‐Kai , Edland, Steven D. , Thomas, Ronald G. , Petersen, Ronald C. , Sano, Mary , Aisen, Paul, Donohue, Michael , Galasko, Douglas , Rissman, Robert A.

Mayo Clinic

Alzheimer's & Dementia | October 8, 2014 | Volume: 11 | Issue: 9 | Pages: 1069-1079

10.1016/j.jalz.2014.07.156 | PMID 25301682 Get It

IntroductionLittle is known about the utility of plasma amyloid beta (Aβ) in clinical trials of Alzheimer's disease (AD).MethodsWe analyzed longitudinal plasma samples from two large multicenter clinical trials: (1) donezepil and vitamin E in mild cognitive impairment (n = 405, 24 months) and (2) simvastatin in mild to moderate AD (n = 225, 18 months).ResultsBaseline plasma Aβ was not related to cognitive or clinical progression. We observed a decrease in plasma Aβ40 and 42 among apolipoprotein E epsilon 4 (APOE ε4) carriers relative to noncarriers in the mild cognitive impairment trial. Patients treated with simvastatin showed a significant increase in Aβ compared with placebo. We found significant storage time effects and considerable plate‐to‐plate variation.DiscussionWe found no support for the utility of plasma Aβ as a prognostic factor or correlate of cognitive change. Analysis of stored specimens requires careful standardization and experimental design, but plasma Aβ may prove useful in pharmacodynamic studies of antiamyloid drugs.
Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer
Abdollah, Firas , Karnes, R. Jeffrey , Suardi, Nazareno , Gandaglia, Giorgio , Fossati, Nicola , Vizziello, Damiano, Sun, Maxine , Karakiewicz, Pierre I., Menon, Mani, Montorsi, Francesco , Briganti, Alberto , Larcher, Alessandro , Cozzarini, Cesare, Cozzarini, C. , Abdollah, Firas

Mayo Clinic

Journal of Clinical Oncology | September 23, 2014 | Volume: 32 | Issue: 35 | Pages: 3939-3947

10.1200/jco.2013.54.7893 | PMID 25245445 Get It

Purpose The role of adjuvant radiotherapy (aRT) in treating patients with pN1 prostate cancer is controversial. We tested the hypothesis that the impact of aRT on cancer-specific mortality (CSM) in these individuals is related to tumor characteristics. Methods We evaluated 1,107 patients with pN1 prostate cancer treated with radical prostatectomy and anatomically extended pelvic lymph node dissection between 1988 and 2010 at two tertiary care centers. All patients received adjuvant hormonal therapy with or without aRT. Regression tree analysis stratified patients into risk groups on the basis of their tumor characteristics and the corresponding CSM rate. Cox regression analysis tested the relationship between aRT and CSM rate, as well as overall mortality (OM) rate in each risk group separately. Results Overall, 35% of patients received aRT. At multivariable analysis, aRT was associated with more favorable CSM rate (hazard ratio [HR], 0.37; P < .001). However, when patients were stratified into risk groups, only two groups of men benefited from aRT: (1) patients with positive lymph node (PLN) count ≤ 2, Gleason score 7 to 10, pT3b/pT4 stage, or positive surgical margins (HR, 0.30; P = .002); and (2) patients with PLN count of 3 to 4 (HR, 0.21; P = .02), regardless of other tumor characteristics. These results were confirmed when OM was examined as an end point. Conclusion The beneficial impact of aRT on survival in patients with pN1 prostate cancer is highly influenced by tumor characteristics. Men with low-volume nodal disease (≤ two PLNs) in the presence of intermediate- to high-grade, non–specimen-confined disease and those with intermediate-volume nodal disease (three to four PLNs) represent the ideal candidates for aRT after surgery.
Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database
Wang, Elyn H. , Yu, James B. , Gross, Cary P. , Smaldone, Marc C. , Shah, Nilay D., Nguyen, Paul L. , Sun, Maxine , Han, Leona C., Kim, Simon P. , Trinh, Quoc‐Dien , Yu, James B

Mayo Clinic

Journal of Urology | September 19, 2014 | Volume: 193 | Issue: 3 | Pages: 820-825

10.1016/j.juro.2014.09.019 | PMID 25242393 Get It

SCCA1/SERPINB3 Promotes Oncogenesis and Epithelial–Mesenchymal Transition via the Unfolded Protein Response and IL6 Signaling
Sheshadri, Namratha , Catanzaro, Joseph M., Bott, Alex J. , Ullman, Erica , Chen, Emily I., Pan, Ji-An , Zhang, Jianhua , Zong, Wei‐Xing , Crawford, Howard C, Sun, Yu , Wu, Song , Crawford, Howard C.

Mayo Clinic

Cancer Research | September 11, 2014 | Volume: 74 | Issue: 21 | Pages: 6318-6329

10.1158/0008-5472.can-14-0798 | PMID 25213322 Get It

Abstract The serine/cysteine protease inhibitor SCCA1 (SERPINB3) is upregulated in many advanced cancers with poor prognosis, but there is limited information about whether it makes functional contributions to malignancy. Here, we show that SCCA1 expression promoted oncogenic transformation and epithelial–mesenchymal transition (EMT) in mammary epithelial cells, and that SCCA1 silencing in breast cancer cells halted their proliferation. SCCA1 overexpression in neu+ mammary tumors increased the unfolded protein response (UPR), IL6 expression, and inflammatory phenotypes. Mechanistically, SCCA1 induced a prolonged nonlethal increase in the UPR that was sufficient to activate NF-κB and expression of the protumorigenic cytokine IL6. Overall, our findings established that SCCA1 contributes to tumorigenesis by promoting EMT and a UPR-dependent induction of NF-κB and IL6 autocrine signaling that promotes a protumorigenic inflammation. Cancer Res; 74(21); 6318–29. ©2014 AACR.